Jurisdiction; % of respondents who had test | ||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|
Variable | NL | PEI | NS | NB | QC | ON | MB | SK | AB | BC | Territories* | Canada |
Age 50–74 yr | ||||||||||||
Family history | 30.9 | 19.6 | 17.8 | 23.3 | 18.5 | 15.4 | 13.1 | 18.5 | 18.5 | 20.0 | 24.9 | 17.5 |
Routine screening | 23.8 | 23.6 | 36.2 | 33.5 | 35.0 | 55.6 | 36.1 | 36.7 | 43.5 | 36.3 | 41.6 | 45.0 |
Age | 2.2 | 9.8 | 4.9 | 8.8 | 6.3 | 15.6 | 8.6 | 7.9 | 8.6 | 5.8 | 9.5 | 10.7 |
Follow-up of problem | 45.9 | 56.4 | 46.9 | 43.1 | 35.6 | 28.5 | 38.3 | 37.7 | 30.7 | 38.7 | 28.9 | 33.1 |
Follow-up of CRC treatment | 3.3 | 0.1 | 3.1 | 2.9 | 2.9 | 1.3 | 1.6 | 3.3 | 1.6 | 1.8 | 2.6 | 1.9 |
Age 40–49 yr | ||||||||||||
Family history | 48.3 | 13.4 | 18.4 | 44.0 | 17.0 | 28.4 | 32.3 | 32.8 | 23.9 | 28.6 | 30.6 | 25.8 |
Routine screening | 17.1 | 0.0 | 14.5 | 11.3 | 14.0 | 27.5 | 14.2 | 4.5 | 10.2 | 12.6 | 19.5 | 18.4 |
Age | 0.0 | 0.0 | 0.0 | 1.2 | 5.2 | 3.0 | 3.7 | 0.9 | 0.7 | 0.6 | 1..2 | 2.8 |
Follow-up of problem | 35.6 | 86.6 | 72.5 | 47.3 | 56.6 | 48.2 | 50.9 | 62.8 | 47.4 | 64.1 | 50.0 | 52.6 |
Follow-up of CRC treatment | 1.2 | 0.0 | 0.0 | 0.4 | 0.1 | 0 | 0 | 0 | 0 | 0.5 | 0.8 | 0.2 |
Age ≥ 74 yr | ||||||||||||
Family history | 11.1 | 12.5 | 12.1 | 15.1 | 9.5 | 7.7 | 10.4 | 16.2 | 8.6 | 10.4 | 12.1 | 9.3 |
Routine screening | 21.2 | 30.7 | 30.8 | 34.3 | 45.3 | 57.7 | 38.9 | 33.5 | 50.0 | 43.8 | 53.4 | 49.2 |
Age | 0.0 | 2.1 | 1.6 | 3.7 | 5.5 | 11.8 | 1.0 | 1.8 | 11.8 | 3.4 | 0.0 | 7.9 |
Follow-up of problem | 65.8 | 56.2 | 49.2 | 50.8 | 34.8 | 33.5 | 44.9 | 51.4 | 29.7 | 38.7 | 28.9 | 36.6 |
Follow-up of CRC treatment | 4.9 | 0.0 | 8.3 | 4.0 | 5.7 | 3.7 | 3.1 | 3.7 | 2.7 | 3.4 | 5.6 | 4.2 |
Note: AB = Alberta, BC = British Columbia, CRC = colorectal cancer, MB = Manitoba, NB = New Brunswick, NL = Newfoundland and Labrador, NS = Nova Scotia, ON = Ontario, PEI = Prince Edward Island, QC = Quebec, SK = Saskatchewan. *Northwest Territories, Yukon and Nunavut.